Rhythm Pharmaceuticals, Inc. insider trading

Every open-market purchase and sale by Rhythm Pharmaceuticals, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $0 0 trades by 0 insiders Insider sales, 5 years $41.7M 23 trades by 9 insiders 3 months later: median −6.9% (−12.4% vs S&P 500)

No insider has bought shares on the open market in five years.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Rhythm Pharmaceuticals, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Rhythm Pharmaceuticals, Inc.’s insiders pay?

From May 21, 2018 to May 19, 2026, 8 insiders reported 1 open-market purchase and 11 sales not made under a pre-set plan in Rhythm Pharmaceuticals, Inc. Twelve months after each purchase was reported, the shares were −62.4% against the S&P 500 on average (median −62.4%), over 1 purchase with a full year of prices; 0% beat the index. After sales, the shares moved −41.7% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on April 1, 2021 into $6,456 by November 2, 2026, −7.6% a year. It held shares 18% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $13,962 (+6.2% a year), and held throughout $20,320 (+13.6%).

Copying Rhythm Pharmaceuticals, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Rhythm Pharmaceuticals, Inc.'s insiders from April 1, 2021, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 18% of the time.

Rhythm Pharmaceuticals, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
German Christopher Paul	Corporate Controller & CAO	0	—	—	2	—	May 19, 2026
Orbimed Capital Gp V LLC	10% owner	0	—	—	2	−18.7% (2)	May 24, 2018
Ra Capital Management, L.P.	Other	0	—	—	2	−70.4% (2)	December 4, 2020
Van Der Ploeg Leonardus H.T.	Chief Scientific Officer	0	—	—	2	−35.3% (2)	June 3, 2019
Cramer Pamela J.	Chief Human Resources Officer	0	—	—	1	−2.5% (1)	August 23, 2022
Foley Todd	Director	0	—	—	1	−70.7% (1)	March 16, 2021
Meeker David P	President and CEO	1	−62.4% (1)	0%	0	—	March 31, 2021
Shah Rajeev M.	10% owner	0	—	—	1	−53.1% (1)	June 29, 2020

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Rhythm Pharmaceuticals, Inc. · Funds · Politicians